Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UCKGX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ADCT-701
|
|||||
| Synonyms |
ADCT 701; ADCT701; LIV-1205 ADC; Humanized anti-DLK1 antibody ADC
Click to Show/Hide
|
|||||
| Organization |
Cancer Research Technology Ltd.; ADC Therapeutics SA
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Neuroblastoma [ICD11:2A00]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Protein delta homolog 1 (DLK1)
|
Antigen Info | ||||
| Payload Name |
SG3199
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
BCN-HydraSpace-Val-Ala-PABC
|
Linker Info | ||||
| Conjugate Type |
Site specifically conjugated using GlycoConnect technology (Synaffix) to PL1601.
|
|||||
| Combination Type |
PL1601
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.